Sp263
ETHICAL DIMENSIONS OF USING AI IN HEALTH CARE: IMPACTS ON DATA PRIVACY, PATIENT SAFETY, PATIENT PREFERENCE, AND PROVIDER AUTONOMY
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
This session will provide an overview of present and future applications of artificial intelligence in the clinical practice of gastroenterology and hepatology, and highlight ethical, legal/regulatory, and equity considerations for use of AI in patient care. Practical strategies will be provided for mitigation of these concerns. The session includes a diverse roster of speakers representing perspectives gleaned by differences in age, gender, race and experience.
This session will provide an overview of present and future applications of artificial intelligence in the clinical practice of gastroenterology and hepatology, and highlight ethical, legal/regulatory, and equity considerations for use of AI in patient care. Practical strategies will be provided for mitigation of these concerns. The session includes a diverse roster of speakers representing perspectives gleaned by differences in age, gender, race and experience.
Presenter
Tracks
Related Products
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
